Wells Fargo & Company Has Lowered Expectations for Incyte (NASDAQ:INCY) Stock Price

Incyte (NASDAQ:INCY) had its price objective lowered by Wells Fargo & Company from $107.00 to $101.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 0.25% from the company’s current price.

Several other research firms have also issued reports on INCY. Morgan Stanley increased their target price on Incyte from $92.00 to $94.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 6th. Wall Street Zen raised shares of Incyte from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Stifel Nicolaus lifted their price objective on shares of Incyte from $119.00 to $120.00 and gave the company a “buy” rating in a report on Wednesday. Royal Bank Of Canada increased their target price on shares of Incyte from $81.00 to $84.00 and gave the stock a “sector perform” rating in a report on Wednesday, October 29th. Finally, HC Wainwright restated a “buy” rating and issued a $135.00 price target on shares of Incyte in a research note on Wednesday. Nine analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $103.94.

Incyte Stock Performance

Shares of INCY stock opened at $100.75 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.32. The firm has a market cap of $20.05 billion, a P/E ratio of 15.72, a P/E/G ratio of 0.59 and a beta of 0.82. The firm’s 50 day moving average price is $101.75 and its 200-day moving average price is $93.86. Incyte has a one year low of $53.56 and a one year high of $112.29.

Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). Incyte had a net margin of 25.03% and a return on equity of 26.34%. The firm had revenue of $1.51 billion during the quarter, compared to analysts’ expectations of $1.35 billion. During the same period in the previous year, the firm earned $1.43 EPS. The firm’s revenue for the quarter was up 27.8% compared to the same quarter last year. As a group, equities research analysts predict that Incyte will post 4.86 EPS for the current year.

Insider Activity

In other news, EVP Mohamed Khairie Issa sold 10,856 shares of Incyte stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total transaction of $1,184,063.92. Following the completion of the sale, the executive vice president directly owned 66,132 shares of the company’s stock, valued at approximately $7,213,017.24. The trade was a 14.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael James Morrissey sold 4,323 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $97.26, for a total value of $420,454.98. Following the completion of the transaction, the executive vice president directly owned 27,507 shares in the company, valued at $2,675,330.82. This trade represents a 13.58% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 95,225 shares of company stock valued at $9,519,745 over the last quarter. Company insiders own 17.80% of the company’s stock.

Hedge Funds Weigh In On Incyte

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Arrowstreet Capital Limited Partnership raised its holdings in Incyte by 701.8% during the second quarter. Arrowstreet Capital Limited Partnership now owns 2,730,648 shares of the biopharmaceutical company’s stock worth $185,957,000 after purchasing an additional 2,390,084 shares in the last quarter. AQR Capital Management LLC raised its stake in Incyte by 21.8% during the 2nd quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company’s stock worth $558,519,000 after acquiring an additional 1,465,286 shares in the last quarter. Norges Bank acquired a new stake in Incyte during the 2nd quarter worth $96,776,000. Pacer Advisors Inc. lifted its position in Incyte by 8,091.6% in the third quarter. Pacer Advisors Inc. now owns 1,248,642 shares of the biopharmaceutical company’s stock valued at $105,897,000 after acquiring an additional 1,233,399 shares during the last quarter. Finally, Marshall Wace LLP acquired a new position in Incyte in the second quarter valued at $82,485,000. 96.97% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Management provided a forward-looking revenue roadmap, outlining 10–13% revenue growth for 2026 and pointing to pipeline expansion and new product launches as growth drivers — this supports a bullish medium-term revenue thesis. Article Title
• Positive Sentiment: HC Wainwright reiterated a Buy rating with a $135 target, reflecting conviction in Incyte’s long-term revenue durability and underappreciated pipeline — a catalyst for upside from some institutional investors. Article Title
• Neutral Sentiment: Q4 earnings call and transcript provide detail: revenue grew strongly (quarterly revenue +27.8% y/y and topped estimates) but EPS missed consensus — investors will parse pipeline comments and margin guidance for signs of sustainable profitability. Article Title
• Neutral Sentiment: Incyte sold Wilmington Bracebridge towers to BPG — a non-core real-estate transaction that slightly improves balance-sheet flexibility but is not material to drug revenue. Article Title
• Neutral Sentiment: Reported short-interest data appears anomalous (shows 0 shares / NaN increase and 0.0 days to cover) — treat as unreliable until clarified by exchanges. (Two entries flagged this oddity.)
• Negative Sentiment: EPS missed consensus on the quarter, prompting a gap-down reaction in shares immediately post-earnings — this short-term selling pressure explains much of the intraday volatility. Article Title
• Negative Sentiment: Royal Bank of Canada cut its price target to $92 and moved to “sector perform,” signaling reduced near-term conviction and pressure on sentiment. (Benzinga / TickerReport coverage noted.)
• Negative Sentiment: Regulatory risk: analysts flagged emerging U.S. “Most Favored Nation” drug-pricing policies as a new risk that could pressure profitability and margins over time — a tangible downside catalyst for revenue forecasts. Article Title

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.